3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Recurrence
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Prostate Cancer Recurrent
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Blast Crisis
1
Interventions
fludarabine
8
Specimen Handling
8
Cyclophosphamide
7
ruxolitinib
5
Whole-Body Irradiation
5
Stem Cell Transplantation
5
Biopsy
5
Azacitidine
5
venetoclax
4
Tacrolimus
4
Injections
4
Cytarabine
4
Busulfan
4
ivosidenib
3
fludarabine phosphate
3
Thiotepa
3
Mycophenolic Acid
3
Melphalan
3
Cyclosporins
3
CPX-351
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
luspatercept
2
X-Rays
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Liposomes
2
Gemtuzumab
2
Daunorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Myeloproliferative Disorders
×
Dasatinib
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled